SEC Form 10-K filed by BridgeBio Oncology Therapeutics Inc.
$BBOT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2026 | $23.00 | Buy | Stifel |
| 1/9/2026 | $24.00 | Outperform | Raymond James |
| 12/5/2025 | $20.00 | Overweight | Morgan Stanley |
| 9/17/2025 | $25.00 | Outperform | Leerink Partners |
| 9/15/2025 | $27.00 | Buy | H.C. Wainwright |
| 8/15/2025 | $21.00 | Overweight | Piper Sandler |
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company's participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare ConferencePresentation: Tuesday, March 10, 2026, at 10:00 a.m. ET. Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at h
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026. The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which wil
10-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00
Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00
Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar